. 2016 Jul 29;6:31. doi: 10.1186/s13561-016-0108-4

Table 2.

Medman trial data for respondents to the DCE survey (continued)

		Trial groups						Intervention subgroups
		Intervention N = 364		P val^a	Control N = 190		P val^a	Still receiving at 24 months N = 188		P val^a	Not receiving at 24 months N = 176		P val^a
		Baseline	12-month follow-up		Baseline	12-month follow-up		Baseline	12-month follow-up		Baseline	12-month follow-up
Costs
			559.12			336.23			327.00			303.40
Costs	mean	1579.40	1568.20	0.90	1242.40	1277.59	0.68	1653.94	1617.20		1499.77	1515.85
Costs	SD	1323.11	1472.54	0.90	1182.63	926.10	0.68	1299.74	1510.42		1346.76	1433.45
Difference in costs			−11.20			35.20			−36.73	0.77		16.08	0.89
Difference in costs			559.65			336.79			325.25	0.77		303.32	0.89
Outcomes
Appropriate treatment score	mean	4.20	4.26	0.55	4.30	4.40	0.51	4.15	4.27	0.44	4.25	4.25	1.00
Appropriate treatment score	SD	0.94	1.03	0.55	0.87	1.01	0.51	0.97	0.94	0.44	0.92	1.12	1.00
SF-6D Score	mean	0.71	0.71	0.55	0.73	0.73	0.66	0.70	0.69	0.14	0.72	0.73	0.28
SF-6D Score	SD	0.14	0.15	0.55	0.14	0.15	0.66	0.14	0.14	0.14	0.14	0.15	0.28
EQ-5D Score	mean	0.73	0.74	0.11	0.73	0.74	0.24	0.73	0.71	0.59	0.73	0.74	0.28
EQ-5D Score	SD	0.24	0.26	0.11	0.24	0.27	0.24	0.23	0.27	0.59	0.26	0.25	0.28
Satisfaction score	mean	42.36	48.30	<0.01	42.90	44.74	0.86	45.74	52.38	0.02	39.26	43.67	<0.01
Satisfaction score	SD	9.89	15.75	<0.01	9.45	17.34	0.86	9.68	15.78	0.02	9.07	14.49	<0.01

^aDifferences between baseline and 24-month follow-up were tested using paired t test statistics